trikafta approv us expand vertex
domin cf increas tp
earlier expect approv trikafta tripl shift launch
upwardli revis guidanc today news solidifi
view vertex remain top-pick larg cap addit clariti
price launch time product note wac price trikafta
per year per pack line price kalydeco higher
orkambi symdeko estim gross-to-net discount line
vertex therapi us previous model net price approxim
patient per year assum modest discount symdeko think price benefit
could upsid vertex forese friction uptak us eventu
expect elig patient least one mutat eventu switch
trikafta follow today approv adjust us probability-of-success
model move forward launch make adjust reflect
disclos price follow chang increas tp
reiter outperform rate
chanc speak compani follow approv
announc price vertex believ price reflect valu trikafta
bring het-min patient also patient least one mutat
known f-ani patient compani also note drug readi launch
expect patient begin access therapi within week focus
increment het-min patient vertex expect f-ani patient eventu switch
trikafta would provid upsid number model homozyg
residu function patient lower cost orkambi symdeko look ahead compani
expect eu approv next year plan expand trikafta patient year old
approv trikafta eu could help reimburs negoti franc england
full portfolio potenti increas pressur patient reimburs treatment
model changes/ risk weve move forward trikafta launch base today
approv move ep risk clinic development
commerci regulatori
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek
busi compani cover research report result investor awar firm may conflict
interest could affect object report investor consid report singl factor make
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
vertex engag develop commerci therapeut
rare diseas includ main franchis cystic fibrosi
scenario assum dcf valu share
cut sg respect assum
posit proof-of-concept data next gener cf asset
also assum posit data updat pipelin asset vx-
gene-edit system
grey sky scenario model less credit trikafta due
lower expect commerci perform regulatori delay
 close
guidanc rais conserv remain achiev think guidanc rais
conserv side indic time take get trikafta suppli chain
cover insur plan still think beatabl
sale alreadi record prior announc forecast cf revenu
estim het-min patient year older
us total us het-min opportun conserv basi expect
trikafta sale grow note rapid uptak
orkambi symdeko first commerci quarter follow approv expect
continu growth symdeko impend launch trikafta contribut
revenu higher end guidanc forecast vs high end
await detail commerci plan trikafta earn call
schedul wednesday octob et dial-in
model chang weve move forward launch trikafta previous
adjust us po increas price assumpt
disclos today result chang forecast revenu
revenu non-gaap ep
non-gaap ep
vertex residu revenu loss incom cs dilut cs charl martineau univers toronto octob
valuat target price deriv dcf analysi use wacc
termin growth forecast cash flow account known
expect product launch patent expir competit threat current
commerci portfolio pipelin beyond forecast period appli termin
growth rate termin cash flow believ vertex continu invest
 bd success replac revenu faster rate eros
risk clinic development clinic trial may neg pipelin asset may
produc expect result commerci product may fail sell well expect
regulatori fda ema may delay declin approv vertex investig product
commerci sale
compani mention price
evan seigerman certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
